行情

AFMD

AFMD

Affimed
NASDAQ

实时行情|Nasdaq Last Sale

2.310
-0.020
-0.86%
盘后: 2.310 0 0.00% 16:00 12/05 EST
开盘
2.320
昨收
2.330
最高
2.352
最低
2.280
成交量
79.04万
成交额
--
52周最高
4.680
52周最低
2.180
市值
1.48亿
市盈率(TTM)
-12.5407
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AFMD 新闻

  • New Strong Sell Stocks for November 27th
  • Zacks.11/27 13:08
  • Edited Transcript of AFMD earnings conference call or presentation 19-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11/26 20:29
  • Affimed N.V. Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
  • Simply Wall St..11/23 11:54
  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.11/22 13:18

更多

所属板块

生物技术和医学研究
-0.70%
制药与医学研究
-0.19%

热门股票

名称
价格
涨跌幅

AFMD 简况

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
展开

Webull提供Affimed NV的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。